• Human lung adenocarcinoma stained with anti-ALK-1 antibody using peroxidase-conjugate and DAB chromogen. Note cytoplasmic stain of adenocarcinoma cells.

Anti-ALK-p80 antibody (1058-1620aa) [ZR305] (STJ180426)

SKU:
STJ180426

£174.50 - £720.50
Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: IHC-P
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit monoclonal antibody anti-ALK-p80 (1058-1620aa) is suitable for use in Immunohistochemistry research applications.
Clonality: Monoclonal
Clone ID: ZR305
Conjugation: Unconjugated
Isotype: IgG
Formulation: Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin
Purification: Affinity purified
Dilution Range: 1:100-200
Storage Instruction: Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C.
Immunogen Region: 1058-1620aa
Specificity: Positive control: Anaplastic large cell lymphoma or Lung adenocarcinoma with ALK translocation
Immunogen: Human ALK-1 protein fragment around aa 1058-1620
Background Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK-1 is typically expressed at low levels in regions of the developing central and peripheral nervous system. ALK-1 may be activated in cancer through multiple mechanisms. The most common mechanism is through the formation of a fusion protein from chromosomal translocations, as in the case of anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors. ALK-1 may also be amplified through mutation, as in neuroblastomas. Various solid tumors, such as non-small cell lung carcinoma (NSCLC) and brain cancers were also found to aberrantly express ALK-1. ALK-1 staining is present within both the nucleus and cytoplasm and is positive in about 60% of ALCL. ALK-1 protein expression by tumor cells is an independent prognostic factor that predicts a favorable outcome.

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance